Phaseline

Companies › AstriVax Therapeutics

AstriVax Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AVX70371
HBV immunotherapeutic
–Phase 1Chronic Hepatitis b–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06989788AVX70371Phase 1Chronic Hepatitis bInfectious diseaseAug 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.